Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
about
Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patientsCurrent status of the prognostic molecular biomarkers in breast cancer: A systematic reviewPrognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasisA plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma.A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies.Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Impact of expression of the uPA system in sarcomas.PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.Preclinical evaluation of [111 In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.Exploring the Role of RGD-Recognizing Integrins in Cancer.uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer.
P2860
Q31021361-6349D904-2E98-4076-8948-9F45C9408FD3Q33598494-17273AA3-218D-4729-BA4B-0F51DBE1BB20Q34995476-771A9709-C28A-467E-B52A-B298AF2B42A0Q36049773-8CCF8964-4DA1-45B7-967C-15D815787C14Q37003184-32065F0D-9FA5-4ED4-BC71-F97027CD6AB3Q37536780-08D57A0E-40E3-4533-85CB-2510198F2460Q37809871-2247589D-AEAA-411B-9EA1-A062E055DEA0Q37899888-72C327AA-ABE3-460B-83B9-551F54B3F432Q38111811-93F14D18-8C02-40F1-B6B9-ADC795363DF1Q38462629-D45A77E1-3DA1-4CDA-8014-2CA9C671FB92Q38690101-E78AA589-C540-4212-9FD8-8D982FE07417Q39456396-B8C26837-4C2E-4C47-8D25-08681C33BBDCQ39644934-674D9F5F-809A-4992-A419-D0CDE77F9935Q41670915-037EB3AA-EF29-4466-ABE9-5C4373887952Q48333132-D502DACA-AE3D-408A-B82B-79A5008085CBQ50014444-FF276B1F-ECC2-4724-91F6-75C308D0B0ACQ54495437-5ABBADB8-8F00-495F-BCD0-EAC9B8A4BA0AQ54960825-567299D4-329D-47F4-A16F-3F5DC946EC84Q55054756-B7CDB64E-2237-40EE-8FB5-6D6E26877106
P2860
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characteristics of the level-o ...... s uPA and its inhibitor PAI-1.
@en
Characteristics of the level-o ...... s uPA and its inhibitor PAI-1.
@nl
type
label
Characteristics of the level-o ...... s uPA and its inhibitor PAI-1.
@en
Characteristics of the level-o ...... s uPA and its inhibitor PAI-1.
@nl
prefLabel
Characteristics of the level-o ...... s uPA and its inhibitor PAI-1.
@en
Characteristics of the level-o ...... s uPA and its inhibitor PAI-1.
@nl
P2093
P2860
P356
P1476
Characteristics of the level-o ...... s uPA and its inhibitor PAI-1.
@en
P2093
Apostolos Gkazepis
John Foekens
Karin Mengele
Manfred Schmitt
Nils Brünner
Rudolf Napieralski
Ute Reuning
Viktor Magdolen
P2860
P304
P356
10.1586/ERM.10.73
P577
2010-10-01T00:00:00Z